Short Term Trading Weekend Lounge: 28-30 Oct, page-89

More sacrilige in the stt thread as this is really a lt play but thought i would mention an announcement made yesterday by my favourite bio MVP.

MVP is a manufacturer of penthrox a non-opiod analgesic currently used in trauma response. This is so far and away a better option for most as no respiratory depression etc prior to arrival at hosp.

Will become the world wide provider of this eventually however the US is probably a couple of years away. Penthrox is not a registered product and hence they needed a moat. This they got through a collaboration with CSIRO where a new method of production for the drug was developed and patented with unspecified but announced as significant cost benefits.

Yesterday they announced a 2 yr collaboration with CSIRO to develop this production platform for other common pharmaceuticals. So assumptions are that their ann re cost benefits are true and they see the process as a disruptive one.

What I also like about MVP is that they are not just expanding jurisdictions where it is available they are also expanding the potential uses of penthrox, from minor surgery ( cysts, colonoscopies) to dental to palliative care.

If you are going to buy exercise some caution as the bots have been in control for a while in between ann driven spikes, illiquid and can be significant gaps on the boards.

Forgot to say Chair bought more on market recently.